Revolution Medicines, Inc. (RVMD): Shareholders' Equity
$1.63B
As of 2025-12-31
$2.61B
As of 2026-06-30
+33.5%
3-year compound annual growth
+28.0%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.63B | -28.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $2.27B | +24.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $1.83B | +166.5% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $685.19M | +13.7% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $602.57M | +26.9% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $474.68M | n/m | 2023-02-27, Balance as of period end |
| 2019-12-31 | -$152.57M | n/m | 2022-02-28, Balance as of period end |
| 2018-12-31 | -$108.42M | n/a | 2021-03-02, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $1.63B | -28.0% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
| Amgen Inc (AMGN) | 2025-12-31 | $8.66B | +47.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Biogen Inc. (BIIB) | 2025-12-31 | $18.26B | +9.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $22.62B | +17.5% |
Compare RVMD, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗